Tumor-infiltrating plasma cell targets as a source for immunotherapies.

IF 56.1 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2026-09-14 Epub Date: 2026-07-27 DOI:10.1016/j.ccell.2026.06.020

Georgia Lattanzi, Daniel Hollern

引用次数: 0

Abstract

Tumor-infiltrating plasma cells are key responders to immunotherapy. In this issue of Cancer Cell, Meyerhoff et al. show that plasma cells from lung lesions of anti-PD-1-treated patients target citrullinated proteins. Engineering CAR T cells with these plasma cells scFv reveals anti-tumor specificity without adverse effects, identifying therapeutic opportunities.

查看原文本刊更多论文

肿瘤浸润性浆细胞靶点作为免疫治疗的来源。

肿瘤浸润性浆细胞是免疫治疗的关键应答者。Meyerhoff等人在本期《Cancer Cell》中表明，抗pd -1治疗患者肺病变的浆细胞靶向瓜氨酸化蛋白。用这些浆细胞scFv改造CAR - T细胞显示出抗肿瘤的特异性而没有副作用，从而确定了治疗机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.